Dry eye syndrome is the second cause of
consultation in ophthalmology. It concerns over 100 million people in the world.
Due to a chronic lack of lubrication and moisture in the eye, its consequences
range from irritation to ocular inflammation of the conjunctiva and corneal
tissues of the eyes. In severe cases, corneal lesions may lead to vision loss.
Ageing populations, pollution, air conditioning, extended use of computers,
contribute to an increase in the prevalence of the syndrome and hence the need
for the development of more efficient products.
Cationorm® is a preservative-free
oil-in-water emulsion resulting from Novasorb® patented technology based on the
electrostatic attraction between the positively charged eye drop and the
negatively charged ocular surface.
Cationorm® acts on all three layers of
the tear film. It combines lubricating and hydrating properties. Cationorm’s
cationic emulsion formulation leads to optimal spreading on the surface of the
eye, replenishment of the tear film lipid layer and prevention of tear
evaporation. Clinical studies have clearly demonstrated Cationorm’s advantages
for patients: tolerance, long-lasting relief and optimal comfort.
Santen has made Cationorm® available in
almost 20 European countries, among others in France, Germany, Finland, Estonia,
Lithuania and Georgia.
Founded in 1890,
Santen is a global company headquartered in Osaka, Japan. Santen researches,
develops and markets ophthalmic products for physicians worldwide. Among
prescription ophthalmic pharmaceuticals, Santen holds the top share within the
Japanese market and is one of the leading ophthalmic companies worldwide. Tokyo
Stock Exchange code 4536. For more information, visit www.santen.com.
Tel: + 33 6 65 54 60